TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT05276570

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: calculated volume to match active treatment by inhalation of nebulized solution
Study: NCT05421455

Intervention type: DRUG
Group type: OTHER
Intervention: Group A
Description: treat participants with biologics
Study: NCT06148038

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CBD Oral
Description: CBD Oral 350mg twice daily for 28 days

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Control
Description: Placebo Control
Study: NCT05421455

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Group B
Description: treat participants with surgery
Study: NCT06274814

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: U/S guided Type 2 Pectoral Nerve Block
Description: 20 mL separates the pectoralis major and minor muscles, while 10 mL separates the serratus and pectoralis major muscles

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: U/S guided RIB combined with the sub-serratus plane block (RISS)
Description: he ipsilateral arm was abducted. RISS was performed. Using a 6-13 MHz linear ultrasound probe was placed medial to the medial border of the scapula in the oblique sagittal plane.. A 100-mm 21-gauge needle was inserted at the level of T5-6 in the ultrasound view. A single dose of 20-mL 0.25% bupivacaine was injected in the interfascial plane between the rhomboid major and intercostal muscles. The spread of the local anesthetic solution under the rhomboid muscle was visualized by ultrasonography. Thereafter, the ultrasound probe was moved caudally and laterally to identify the tissue plane between the serratus anterior and external intercostal muscles for the sub-serratus block at the T8-9 level. The needle was advanced from its previous position, and an additional 20 mL of 0.25% bupivacaine was injected.
Study: NCT06078579

Intervention type: DIAGNOSTIC_TEST
Intervention: Leptin
Description: Assessment of salivary and serum leptin levels in oral lichen planus patients and healthy controls

Intervention type: DIAGNOSTIC_TEST
Intervention: Leptin
Description: Assessment of salivary and serum leptin levels in oral lichen planus patients and healthy controls
Study: NCT05460442

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Fascia iliaca group
Description: Patients will receive Ultrasound-Guided fascia iliaca compartment block in the supine position after sterilization of groin area. The needle will be inserted in-plane with the transducer. The needle tip will be advanced through the fascia iliaca and inserted further cephalad just below the fascia iliaca into the iliacus muscle. 0.5 mL/kg of (0.25%) bupivacaine will be injected and visualized moving cephalad away from the needle tip
Study: NCT05287880

Intervention type: DIAGNOSTIC_TEST
Intervention: Dynamic PET/CT
Description: After transmission CT scan for subsequent PET data attenuation correction, continual dynamic clinical PET scans were performed in a single bed position immediately after 18F-FAPI intravenously injection (210 ± 30 MBq) in list mode for 60 minutes in supine position, dynamic 48 time frames PET/CT imaging was obtained. And then underwent whole body static PET scan.

Intervention type: DIAGNOSTIC_TEST
Intervention: Dynamic PET/CT
Description: After transmission CT scan for subsequent PET data attenuation correction, continual dynamic clinical PET scans were performed in a single bed position immediately after 18F-FAPI intravenously injection (210 ± 30 MBq) in list mode for 60 minutes in supine position, dynamic 48 time frames PET/CT imaging was obtained. And then underwent whole body static PET scan.
Study: NCT05328206

Intervention type: OTHER
Intervention: Standard of care for intubated children
Description: Patient ventilated through a cuffed endotracheal tube and having a cuff leak test prior extubation
Study: NCT05561322

Intervention type: OTHER
Intervention: Consultation involving pain evaluation, questionnaires and the Lasègue Manoeuver
Description: Raising the lower limb with the knee in extension reproduces sciatica pain if there is an impression of discal pain with its origin at the roots of the sciatica nerve L5 and S1. This test is evaluated by the degree of elevation of the lower limb relative to the examination table. During the Lasègue manoeuvre the sciatica pain is improved during dorsal flexion of the foot.The doctor notes whether the Lasègue manoeuvre done on the healthy side exacerbates the pain on the opposite side. It is said that contralateral Lasègue sign is positive.

Intervention type: OTHER
Intervention: Consultation involving pain evaluation, questionnaires and the Lasègue Manoeuver
Description: Raising the lower limb with the knee in extension reproduces sciatica pain if there is an impression of discal pain with its origin at the roots of the sciatica nerve L5 and S1. This test is evaluated by the degree of elevation of the lower limb relative to the examination table. During the Lasègue manoeuvre the sciatica pain is improved during dorsal flexion of the foot.The doctor notes whether the Lasègue manoeuvre done on the healthy side exacerbates the pain on the opposite side. It is said that contralateral Lasègue sign is positive.

Intervention type: OTHER
Intervention: Magnetic Resonance Imaging of the lumbar spine
Description: Sagittal proton density-weighted Dixon sequence on the lumbar spine and axial T2-weighted spin echo sequence on the lumbar discs.
Study: NCT05900856

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: low caloric diet regimen
Description: lipids approximately (20: 35%) of total caloric intake, protein approximately (10: 35%) of total caloric intake and high complexed carbohydrate intake approximately (45: 65%) of total caloric intake (with increased fiber-rich whole grain breads, cereals, fruits and vegetables), for eight weeks.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: low caloric diet regimen
Description: lipids approximately (20: 35%) of total caloric intake, protein approximately (10: 35%) of total caloric intake and high complexed carbohydrate intake approximately (45: 65%) of total caloric intake (with increased fiber-rich whole grain breads, cereals, fruits and vegetables), for eight weeks.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ultrasound cavitation
Description: patients will assume standing position, the abdominal area will be divided vertically into 2 equal sections, right and left segment, extending bilaterally from the line stretching between the mid axilla above and the iliac crest below, and upward from center of diaphragm to the midpoint extending between two iliac crest below, then from supine lying position the cavitation head will be applied on each abdominal segment for 15 minutes with total treatment time 30 minutes twice per week for eight weeks
Study: NCT05962151

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nalbuphine ER
Description: Oral tablets

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Oral tablets
Study: NCT05711862

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SUVO
Description: Participants will receive 20mg of SUVO for 7 days. Participants will be directed to take the medication between 9:30 PM and 10:00PM.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SUVO
Description: Participants will receive 20mg of SUVO for 7 days. Participants will be directed to take the medication between 9:30 PM and 10:00PM.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Participants will receive 0mg of placebo for 7 days. Participants will be directed to take the medication between 9:30 PM and 10:00PM.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Participants will receive 0mg of placebo for 7 days. Participants will be directed to take the medication between 9:30 PM and 10:00PM.
Study: NCT04617184

Intervention type: OTHER
Intervention: NO INTERVENTION
Description: THERE IS NO INTERVENTION TO THIS TRIAL. THIS IS A REGISTRY
Study: NCT06259422

Intervention type: DRUG
Group type: OTHER
Intervention: Iohexol
Description: Subjects will receive a single bolus of 5 mL of Omnipaque 300 (containing 3235 mg iohexol)

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: 125I-iothalamate and 131I-hippuran
Description: Subjects will receive 125I-iothalamate and 131I-hippuran as part of their routine clinical care.
Study: NCT05547425

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Blur Obfuscation
Description: Blurring is applied to objects and people in the background of images.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Edge Obfuscation
Description: Objects and people in the background of images are replaced with an outline of the object.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Cartoon Obfuscation
Description: Blurring is applied to objects and people in the background of images and the wearer's face is concealed with cartoon faces.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Raw images
Description: No editing is performed on images.
Study: NCT05414539

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: OptiCogs Online
Description: A multicomponent intervention to rehabilitate cognitive deficits in people post-stroke
Study: NCT05873543

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: smartphone-assisted hybrid cardiac rehabilitation (SHCR)
Description: The 12-week case manager-led SHCR program includes:~* Customized exercise prescriptions following ACSM's heart failure guidelines.~* A hybrid program combining in-person sessions, home self-exercise, and videoconferencing for exercise coaching(optional), supported by a smartphone app.~* Case managers instruct patients on a communication app for weekly follow-ups, health education messages, exercise reminders, and progress tracking, including metrics like blood pressure, heart rate, weight, and symptoms.
Study: NCT04807985

Intervention type: DEVICE
Intervention: JVPHome and ultrasound
Description: Remote clinician assessment of JVP height using the JVPHome, and ultrasound based assessment of JVP height in the same patients.
Study: NCT05803018

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BL-B01D1
Description: Administration by intravenous infusion
Study: NCT05688930

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: PENMT (Experimental Group)
Description: The neuromuscular injury prevention intervention protocol contains field work activities that involve proprioceptive exercises, flexibility, and specific and general muscle strength of the MMII and trunk soccer players.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: FIFA 11+ (Control Group)
Description: Treatment or experimental condition. 1: FIFA 11+ Program
Study: NCT05494684

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Multisensoral Nature-based Intervention
Description: The intervention includes a multi-sensory nature experience using natural materials and a virtually created natural environment.
Study: NCT05276284

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Atezolizumab, 6-mercaptopurine, 6-thioguanine
Description: Combination therapy with Atezolizumab, 6-mercaptopurine and 6-thioguanine
Study: NCT05561322

Intervention type: OTHER
Intervention: Magnetic Resonance Imaging of the lumbar spine
Description: Sagittal proton density-weighted Dixon sequence on the lumbar spine and axial T2-weighted spin echo sequence on the lumbar discs.
Study: NCT06189144

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Emollient cream treatment
Description: Rilastil Difesa Sterile cream

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: no treatment
Description: no treatment
Study: NCT05961072

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Vibrotactile sensory feedback device
Description: The company Saphenus Medical Technology GmbH will provide all of the devices for this study. The non-invasive vibrotactile sensory feedback device consists of 4 vibration -motors, which are placed in a cuff or pant on the patient's residual limb (RL). Furthermore, the system consists of a foot sole with integrated sensors and transmitters. The patient will put the sole of their foot into the shoe of the amputated side.~There are 4 sensors matching the vibration motors - 3 under the forefoot and 1 on the heel - in the foot sole. Depending on whether the patient loads their forefoot or their heel while walking, the assigned vibration motor vibrates on the skin of their RL. The patient will learn which vibration motor is assigned to their forefoot and which to their heel. This gives the patient sensory feedback without having to check with their eyes which part of the prosthetic foot is currently touching the ground.
Study: NCT05236738

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atazanavir
Description: Specified dose on specified days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atazanavir
Description: Specified dose on specified days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atazanavir
Description: Specified dose on specified days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cobicistat
Description: Specified dose on specified days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cobicistat
Description: Specified dose on specified days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cobicistat
Description: Specified dose on specified days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atazanavir/Cobicistat Mini-tablet
Description: Specified dose on specified days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atazanavir/Cobicistat Mini-tablet
Description: Specified dose on specified days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atazanavir/Cobicistat Mini-tablet
Description: Specified dose on specified days
Study: NCT06257927

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Tuko Pamoja
Description: Tuko Pamoja, We are Together in Kiswahili; This intervention, delivered by lay counselors and through existing community social structures, focuses on improving family relationships and mental health with content derived from evidence-based practices; these include solution-focused family therapy and cognitive behavioral strategies. It is components based, with modules delivered based on need. Tuko Pamoja includes a smart phone component to support psychoeducation components and data collection. The content and structure has been adapted in both content and implementation model based on formative research in this context.
Study: NCT05334342

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Low-GI Diet
Description: Participants will be given a low glycemic index diet

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: High-GI Diet
Description: Participants will be given a high glycemic index diet
Study: NCT06649968

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: DESC-Glove (active)
Description: Rehabilitation treatment for the upper limb using the DESC-Glove device. The protocol includes 8 exercises, each lasting 2 to 3 minutes. The treatment is conducted daily under the supervision of a therapist and consists of two 20-minute sessions per day, with a 10-minute break in between for neuro-muscular and attentional recovery. The treatment is performed three times a week, totaling 24 sessions over a 4-week period. During each session, patients will wear the DESC-Glove on the affected hand, receiving vibratory stimuli that are synchronized with the exercises being performed.
Study: NCT06391710

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HRS9531
Description: subcutaneous

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: subcutaneous
Study: NCT06649968

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: DESC-Glove (sham)
Description: Rehabilitation treatment for the upper limb using the DESC-Glove device. The protocol includes 8 exercises, each lasting 2 to 3 minutes. The treatment is conducted daily under the supervision of a therapist and consists of two 20-minute sessions per day, with a 10-minute break in between for neuro-muscular and attentional recovery. The treatment is performed three times a week, totaling 24 sessions over a 4-week period. During each session, patients will wear the DESC-Glove on the affected hand, but will not receive any vibratory stimuli.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Traditional rehabilitation
Description: Traditional rehabilitation treatment for the upper limb. The protocol includes 8 exercises, each lasting 2 to 3 minutes. The treatment is conducted daily under the supervision of a therapist and consists of two 20- minute sessions per day, with a 10-minute break in between for neuro-muscular and attentional recovery. The treatment is performed three times a week, totaling 24 sessions over a 4-week period. The DESC- Glove will not be used during this treatment.
Study: NCT06651112

Intervention type: DRUG
Intervention: Antipsychotic drugs
Description: Any Antipsychotic drugs prescripbe as standrd of care for this specific populaton
Study: NCT05535075

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Vancomycin model-informed precision dosing
Description: A dosing calculator is used for a posteriori calculation of vancomycin dose using a target AUC/MIC between 400-600 mg\*h/L

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Vancomycin
Description: Vancomycin treatment

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vancomycin
Description: Vancomycin treatment
Study: NCT04969237

Intervention type: DIAGNOSTIC_TEST
Intervention: Vitamine D in blood samples
Description: vitamine D values

Intervention type: DIAGNOSTIC_TEST
Intervention: Vitamine D in blood samples
Description: vitamine D values

Intervention type: DIAGNOSTIC_TEST
Intervention: Vitamine D in blood samples
Description: vitamine D values

Intervention type: DIAGNOSTIC_TEST
Intervention: Vitamine D in blood samples
Description: vitamine D values
Study: NCT06086145

Intervention type: OTHER
Intervention: No intervention
Description: No intervention
Study: NCT06310551

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oral VH4524184
Description: VH4524184 to be taken orally.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oral VH4524184
Description: VH4524184 to be taken orally.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oral VH4524184
Description: VH4524184 to be taken orally.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oral VH4524184
Description: VH4524184 to be taken orally.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oral VH4524184
Description: VH4524184 to be taken orally.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oral VH4524184
Description: VH4524184 to be taken orally.
Study: NCT05782725

Intervention type: OTHER
Intervention: Comparison of laboratory test results in women in the 4 study arms
Description: Comparison of AMH, FSH, LH, estradiol, AFC/ ovarian volume on ultrasound in women in the 4 study arms

Intervention type: OTHER
Intervention: Comparison of laboratory test results in women in the 4 study arms
Description: Comparison of AMH, FSH, LH, estradiol, AFC/ ovarian volume on ultrasound in women in the 4 study arms

Intervention type: OTHER
Intervention: Comparison of laboratory test results in women in the 4 study arms
Description: Comparison of AMH, FSH, LH, estradiol, AFC/ ovarian volume on ultrasound in women in the 4 study arms

Intervention type: OTHER
Intervention: Comparison of laboratory test results in women in the 4 study arms
Description: Comparison of AMH, FSH, LH, estradiol, AFC/ ovarian volume on ultrasound in women in the 4 study arms
Study: NCT05088369

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HM201
Description: HM201 will be administered intravenously.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo will be administered intravenously.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HM201
Description: HM201 will be administered intravenously.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo will be administered intravenously.
Study: NCT05797831

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Navtemadlin
Description: Navtemadlin is an experimental MDM2 anticancer drug taken by mouth

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Navtemadlin
Description: Navtemadlin is an experimental MDM2 anticancer drug taken by mouth

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Navtemadlin
Description: Navtemadlin is an experimental MDM2 anticancer drug taken by mouth

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Navtemadlin
Description: Navtemadlin is an experimental MDM2 anticancer drug taken by mouth

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Navtemadlin Placebo
Description: Navtemadlin placebo is a placebo that is the same in appearance to navtemadlin drug taken by mouth

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Navtemadlin Placebo
Description: Navtemadlin placebo is a placebo that is the same in appearance to navtemadlin drug taken by mouth
Study: NCT06178861

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Group wearing a radiotherapy bra
Description: Group wearing a radiotherapy bra
Study: NCT06171269

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiation
Description: Radiation to the prostate gland will be given daily (Mon-Friday) for 4 weeks.

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: MRI
Description: The study doctor will use an MRI scan to take pictures of the prostate gland. These images of the prostate gland will let the study doctor know which areas of the prostate contain cancer cells that need to be targeted with higher doses of radiation and which uninvolved areas to target with lower doses of radiation.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Androgen Deprivation Therapy
Description: Treatment of treating physician choice will be given for 6-24 months.
Study: NCT04665843

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Atezolizumab
Description: Atezolizumab at a fixed dose of 1200 mg will be administered by intravenous (IV) infusion Q3W on Day 1 of each 21-day cycle.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atezolizumab
Description: Atezolizumab at a fixed dose of 1200 mg will be administered by intravenous (IV) infusion Q3W on Day 1 of each 21-day cycle.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tiragolumab
Description: Tiragolumab at a fixed dose of 600 mg will be administered by IV infusion Q3W on Day 1 of each 21-day cycle.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo will be administered by IV infusion Q3W on Day 1 of each 21-day cycle.
Study: NCT06637631

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SAR441566
Description: Pharmaceutical form: Tablet Route of administration: Oral

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SAR441566
Description: Pharmaceutical form: Tablet Route of administration: Oral

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SAR441566
Description: Pharmaceutical form: Tablet Route of administration: Oral

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: SAR441566 matching Placebo
Description: Pharmaceutical form: Tablet Route of administration: Oral